A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Explore Jagadish Nimmagadda’s journey in cloud computing security, leadership, and innovation. Learn how his expertise in AWS ...

The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the ...

Microsoft Threat Intelligence uncovered a macOS vulnerability that could potentially allow an attacker to bypass the ...

According to a new comprehensive report from The Insight Partners, the global extended detection and response market is ...

EDRSilencer is an open-source tool inspired by MdSec NightHawk FireBlock. This is a proprietary penetration testing tool that ...

Red team tool EDRSilencer has been used by hackers to make the Windows Filtering Platform block a long list of EDR products ...

Newer technologies like automation and AI may offer new solutions to this age-old cybersecurity problem, but they can also be double-edged swords.

The global cybersecurity technology market is growing due to several factors such as technological advancements the rise in ...

The global cybersecurity market size was valued USD 274.2 billion in 2023. By 2032, this figure is projected to reach around ...

MeiraGTx’s AAV-GAD gene therapy trial met its safety and tolerability objectives. Credit: MicroOne. A Phase I/II trial (NCT05603312) with MeiraGTx‘s AAV-GAD Parkinson’s disease gene therapy has met ...